Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.
Jolanta SkarbalieneJesper Mosolff MathiesenBjarne Due LarsenChristian ThorkildsenYvette Miata PetersenPublished in: BMC gastroenterology (2023)
Glepaglutide has anti-inflammatory and intestinotrophic effects without the need for pre-treatment in a rat model of small intestinal inflammation. Thus, glepaglutide is of potential clinical interest for patients with IBD.